3 Neil Woodford High-Yield Picks: GlaxoSmithKline plc, NEXT plc And Legal & General Group Plc

GlaxoSmithKline plc (LON:GSK), NEXT plc (LON:NXT) and Legal & General Group Plc (LON:LGEN) are Woodford’s heavyweight high-yield picks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Top fund manager Neil Woodford is not one for chasing high yields that subsequently prove unsustainable. He was out of banks well before the credit crunch smashed payouts in the sector, and he’s dodged the current round of slashed dividends in the mining industry.

But he does hold some stocks that offer yields well above the market average. His FTSE 100 heavyweights with the highest payouts are GlaxoSmithKline (LSE: GSK), Next (LSE: NXT) and Legal & General (LSE: LGEN).

Pharma favourite

Glaxo is set to return to earnings growth in 2016 after a number of difficult years. In its results for 2015, released earlier this month, the company reported a decline in core earnings of 15% (at constant exchange rates). This was actually a little better than guidance, but even more welcome was management’s expectation of double-digit growth in 2016.

The integration of new businesses in Vaccines and Consumer Healthcare, the restructuring of the Global Pharmaceuticals division and the acceleration of new product sales should all drive earnings upwards in coming years. In fact, new product sales are now expected to reach management’s £6bn target up to two years earlier than previously guided (2018, rather than 2020).

The board has reiterated its intention to pay a flat 80p dividend for 2016 and 2017, giving an annual yield of 5.8% at a recent share price of 1,386p. With dividend cover improving as earnings growth kicks in, payouts should then be able to resume a healthy upwards trajectory.

Fashion focus

High street stalwart Next has yet to release results for its financial year ended 30 January, but has provided a trading update. The company said an unseasonably warm November and December would drag full-year sales down to just below the bottom end of previous guidance, but that profit was still on track thanks to good control of margins, costs and stock.

The company has paid out 153p of ordinary dividends during the fiscal year and 230p of special dividends, giving a total running yield of 5.7% at a recent share price of 6,750p. Special dividends (and share buybacks) are an ongoing feature of Next’s focus on delivering value to shareholders. And an increase in payouts is forecast for the year to January 2017, lifting the yield to 6%.

Insurance income

Analysts expect Legal & General to declare a final dividend of 9.9p when it announces its annual results on 15 March. Added to the last interim payout of 3.45p, this gives 13.35p, and a yield of 6.1% at a recent share price of 218p. Expected growth drives the forecast yield for 2016 up to 6.5%.

Something of a changing of the guard is underway at Legal & General, with separate announcements of the retirement of both the chairman and finance director having been made in recent months. Investors have also been a little unnerved by L&G’s potential exposure to bonds in the troubled oil and mining sectors. However, the company detailed its limited exposure to these sectors earlier this month.

Woodford and his team remain “very positive on the prospect of consistent and attractive long-term dividend growth”.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »